EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

SUV remains the most widely used PET parameter to evaluate NHLs because it is directly associated with lymphoma aggressiveness.

Paul Critchett battled Veterans Affairs for years, certain his terminal cancer diagnosis stemmed from radiation exposure. On ...

Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.

Thousands of blood cancer survivors have received life-saving treatment thanks to a small army of inspired cyclists, hikers, ...

A study in Cancer compared the accuracy of five risk scores for time to treatment in CLL, including the IPS-E, CR0, AIPS-E, ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...

CART, a next-gen CAR-T therapy for improved targeting and functionality to address this. “ALA-CART improves the ability of ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...